Processa Pharmaceuticals Future Growth
Future criteria checks 0/6
Processa Pharmaceuticals's earnings are forecast to decline at 5.7% per annum. EPS is expected to grow by 53.1% per annum.
Key information
-5.7%
Earnings growth rate
53.1%
EPS growth rate
Pharmaceuticals earnings growth | 24.0% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 05 Dec 2024 |
Recent future growth updates
Recent updates
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Dec 12Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Oct 20Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
Aug 12We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Jul 07We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate
Jan 20Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
Aug 26Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow
Jun 15What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?
Mar 15Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look
Jan 29How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?
Jan 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -13 | N/A | N/A | 1 |
12/31/2024 | N/A | -12 | N/A | N/A | 1 |
9/30/2024 | N/A | -12 | -11 | -11 | N/A |
6/30/2024 | N/A | -10 | -9 | -9 | N/A |
3/31/2024 | N/A | -10 | -8 | -8 | N/A |
12/31/2023 | N/A | -11 | -8 | -8 | N/A |
9/30/2023 | N/A | -22 | -8 | -8 | N/A |
6/30/2023 | N/A | -26 | -10 | -10 | N/A |
3/31/2023 | N/A | -28 | -10 | -10 | N/A |
12/31/2022 | N/A | -27 | -10 | -10 | N/A |
9/30/2022 | N/A | -18 | -10 | -10 | N/A |
6/30/2022 | N/A | -15 | -8 | -8 | N/A |
3/31/2022 | N/A | -13 | -8 | -8 | N/A |
12/31/2021 | N/A | -11 | -9 | -9 | N/A |
9/30/2021 | N/A | -23 | -8 | -8 | N/A |
6/30/2021 | N/A | -23 | -7 | -7 | N/A |
3/31/2021 | N/A | -20 | -5 | -5 | N/A |
12/31/2020 | N/A | -19 | -3 | -3 | N/A |
9/30/2020 | N/A | -6 | -1 | -1 | N/A |
6/30/2020 | N/A | -4 | -2 | -2 | N/A |
3/31/2020 | N/A | -4 | -3 | -3 | N/A |
12/31/2019 | N/A | -4 | -3 | -3 | N/A |
9/30/2019 | N/A | -3 | -3 | -3 | N/A |
6/30/2019 | N/A | -3 | -3 | -3 | N/A |
3/31/2019 | N/A | -3 | -3 | -3 | N/A |
12/31/2018 | N/A | -4 | -4 | -4 | N/A |
9/30/2018 | N/A | -4 | -4 | -4 | N/A |
6/30/2018 | N/A | -4 | N/A | -4 | N/A |
3/31/2018 | N/A | -3 | N/A | -3 | N/A |
12/31/2017 | N/A | -2 | N/A | -2 | N/A |
12/31/2016 | N/A | -2 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCSA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PCSA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PCSA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if PCSA's revenue is forecast to grow faster than the US market.
High Growth Revenue: PCSA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PCSA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 08:41 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Processa Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Robin Garner Kalley | Craig-Hallum Capital Group LLC |
Raghuram Selvaraju | H.C. Wainwright & Co. |
François Brisebois | Oppenheimer & Co. Inc. |